Literature DB >> 34055208

Novel Pyrazolo[3,4-b]pyrazines as SHP2 Inhibitors for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 34055208      PMCID： PMC8155244          DOI： 10.1021/acsmedchemlett.1c00173

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.

Authors:  D Lucas Kerr; Franziska Haderk; Trever G Bivona
Journal:  Curr Opin Chem Biol       Date:  2021-01-06       Impact factor: 8.822

Review 2.  Emerging chemical scaffolds with potential SHP2 phosphatase inhibitory capabilities - A comprehensive review.

Authors:  Rati Kailash Prasad Tripathi; Senthil Raja Ayyannan
Journal:  Chem Biol Drug Des       Date:  2020-11-15       Impact factor: 2.817

Review 3.  Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.

Authors:  Dadong Shen; Wenxia Chen; Jinlin Zhu; Guofeng Wu; Runpu Shen; Meiyang Xi; Haopeng Sun
Journal:  Eur J Med Chem       Date:  2020-02-06       Impact factor: 6.514

Review 4.  Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.

Authors:  Xinrui Yuan; Hong Bu; Jinpei Zhou; Chao-Yie Yang; Huibin Zhang
Journal:  J Med Chem       Date:  2020-06-10       Impact factor: 7.446

Review 5.  Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.

Authors:  Rangan Mitra; Senthil R Ayyannan
Journal:  ChemMedChem       Date:  2020-12-16       Impact factor: 3.466

Review 6.  Targeting SHP2 as a promising strategy for cancer immunotherapy.

Authors:  Qianqian Liu; Jiao Qu; Mingxia Zhao; Qiang Xu; Yang Sun
Journal:  Pharmacol Res       Date:  2019-12-12       Impact factor: 7.658
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.